Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IBIONASDAQ:OBSVNASDAQ:TNFANASDAQ:TSBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$0.73-9.0%$2.41$0.64▼$6.89$12.03M1.19418,799 shs723,421 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shsN/ATNFATNF Pharmaceuticals$0.22+23.4%$0.28$0.16▼$2.16$2.23M2.13678,775 shs15.54 million shsTSBXTurnstone Biologics$0.35+2.9%$0.37$0.29▼$3.05$8.10M1.29217,075 shs245,646 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio-8.99%-14.24%-38.30%-79.78%-61.68%OBSVObsEva0.00%0.00%0.00%0.00%0.00%TNFATNF Pharmaceuticals+23.39%+15.45%-18.45%-61.16%+22,049,900.00%TSBXTurnstone Biologics+2.91%+5.26%-7.19%-10.28%-87.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBIOiBio1.4527 of 5 stars3.50.00.00.01.70.00.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATSBXTurnstone Biologics2.6329 of 5 stars2.85.00.00.01.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBIOiBio 3.00Buy$4.30490.58% UpsideOBSVObsEva 0.00N/AN/AN/ATNFATNF Pharmaceuticals 0.00N/AN/AN/ATSBXTurnstone Biologics 1.50Reduce$0.4528.61% UpsideCurrent Analyst Ratings BreakdownLatest TNFA, OBSV, IBIO, and TSBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBIOiBio$375K32.07N/AN/A$1.41 per share0.52OBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00TNFATNF PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ATSBXTurnstone Biologics$19.31M0.42N/AN/A$4.27 per share0.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ATNFATNF Pharmaceuticals-$4M-$11.45N/A∞N/AN/A-180.71%-84.27%5/21/2025 (Estimated)TSBXTurnstone Biologics-$55.20M-$2.73N/AN/AN/AN/A-105.99%-87.27%N/ALatest TNFA, OBSV, IBIO, and TSBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TSBXTurnstone Biologics-$0.26-$0.51-$0.25-$0.51N/AN/A4/11/2025Q4 2024TNFATNF PharmaceuticalsN/A-$0.66N/A-$0.66N/AN/A3/28/2025Q4 2024TSBXTurnstone Biologics-$0.69-$0.56+$0.13-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBIOiBioN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBIOiBio0.051.761.76OBSVObsEvaN/A0.610.61TNFATNF PharmaceuticalsN/A1.721.72TSBXTurnstone BiologicsN/A3.753.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBIOiBio7.90%OBSVObsEva17.52%TNFATNF Pharmaceuticals9.64%TSBXTurnstone Biologics52.51%Insider OwnershipCompanyInsider OwnershipIBIOiBio0.58%OBSVObsEva14.40%TNFATNF Pharmaceuticals1.21%TSBXTurnstone Biologics32.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBIOiBio10016.52 million9.82 millionN/AOBSVObsEva5077.97 million66.74 millionNot OptionableTNFATNF Pharmaceuticals610.13 million2.72 millionN/ATSBXTurnstone Biologics8223.14 million15.70 millionNot OptionableTNFA, OBSV, IBIO, and TSBX HeadlinesRecent News About These CompaniesTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...May 8, 2025 | gurufocus.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsMay 8, 2025 | globenewswire.comTurnstone Biologics reports Q4 EPS (56c) vs (73c) last yearMarch 31, 2025 | markets.businessinsider.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | investing.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comTurnstone Biologics stock plunges to 52-week low of $0.4February 11, 2025 | msn.comTurnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?February 7, 2025 | zacks.comTurnstone Biologics to explore strategic alternativesFebruary 6, 2025 | thepharmaletter.comTurnstone ends last remaining clinical program due to costs, plots more layoffsFebruary 5, 2025 | fiercebiotech.comTurnstone Biologics halts TIDAL-01 development, seeks alternativesFebruary 5, 2025 | msn.comTurnstone Biologics downgraded to Neutral from Overweight at Piper SandlerFebruary 5, 2025 | markets.businessinsider.comTurnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True PotentialFebruary 5, 2025 | bovnews.comTurnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives ReviewFebruary 4, 2025 | quiverquant.comTurnstone Biologics Announces Plans to Explore Strategic AlternativesFebruary 4, 2025 | finance.yahoo.comBofA downgrades Turnstone to Underperform on unfavorable marketNovember 16, 2024 | markets.businessinsider.comTurnstone Biologics downgraded to Underperform from Neutral at BofANovember 16, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Turnstone Biologics Corp. (TSBX)November 15, 2024 | markets.businessinsider.comTurnstone Biologics Faces Financial and Operational ChallengesNovember 14, 2024 | markets.businessinsider.comTurnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsNovember 12, 2024 | markets.businessinsider.comWhat’s Behind the 18.75% Gain in Turnstone Biologics Corp (TSBX) Stock? Find Out Now!November 7, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, OBSV, IBIO, and TSBX Company DescriptionsiBio NYSE:IBIO$0.73 -0.07 (-8.99%) As of 05/14/2025 04:00 PM EasterniBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.TNF Pharmaceuticals NASDAQ:TNFA$0.22 +0.04 (+23.39%) As of 05/14/2025 04:00 PM EasternTNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Turnstone Biologics NASDAQ:TSBX$0.35 +0.01 (+2.91%) As of 05/14/2025 04:00 PM EasternTurnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
